Back to Search
Start Over
Cefozopran, meropenem, or imipenem–cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial
- Source :
- Journal of Infection and Chemotherapy. 21:16-22
- Publication Year :
- 2015
- Publisher :
- Elsevier BV, 2015.
-
Abstract
- We conducted an open-label, randomized study to evaluate the clinical efficacy of cefozopran, meropenem or imipenem-cilastatin using cefepime as a control in febrile neutropenia (FN) patients. Three hundred and seventy-six patients received cefepime, cefozopran, meropenem or imipenem-cilastatinas initial therapy for FN. The primary endpoint was the non-inferiority of response rates including modification at day 7 in cefozopran, meropenem or imipenem-cilastatin patients compared with cefepime in the per-protocol population (delta = 10%). The response rates for cefozopran, meropenem and imipenem-cilastatin were not significantly different compared with cefepime (cefozopran: 54/90 (60%), meropenem: 60/92 (65%), and IPM/CS: 63/88 (72%) versus cefepime: 56/85 (66%) (p = 0.44, 1.0 and 0.51, respectively)), and the differences in treatment success for cefozopran, meropenem and imipenem-cilastatin compared with cefepime were -5.9% (95% confidence interval (CI): -20.1-8.4), -0.7% (95% CI: -14.6-13.3), and 5.7% (95% CI: -8.1-19.4), respectively. The same tendency was seen in the modified intention-to-treat population. Based on the evaluation of initial drug efficacy performed on days 3-5, there was no significant difference between the four drugs. In the subgroup with an absolute neutrophil count ≤ 100 × 10(6)/L for longer than seven days, there was significantly better efficacy in the carbapenem arm compared to 4th generation beta-lactams (52% versus 27% at days 3-5, p = 0.006, and 76% versus 48% at day 7, p = 0.002). Our results suggest that the effects of these four drugs as empiric therapy were virtually the same for adult FN patients, although non-inferiority was shown only in imipenem-cilastatin compared with cefepime (clinical trial number: UMIN000000462).
- Subjects :
- Adult
Male
Microbiology (medical)
medicine.medical_specialty
Carbapenem
Adolescent
Cefepime
Population
Cilastatin, Imipenem Drug Combination
Meropenem
Young Adult
Internal medicine
polycyclic compounds
medicine
Cefozopran
Humans
Pharmacology (medical)
Prospective Studies
Chemotherapy-Induced Febrile Neutropenia
education
Aged
Aged, 80 and over
education.field_of_study
business.industry
Imipenem/cilastatin
Middle Aged
biochemical phenomena, metabolism, and nutrition
medicine.disease
Anti-Bacterial Agents
Cephalosporins
Drug Combinations
Imipenem
Infectious Diseases
Cilastatin
Anesthesia
Absolute neutrophil count
Thienamycins
business
Febrile neutropenia
medicine.drug
Subjects
Details
- ISSN :
- 1341321X
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Journal of Infection and Chemotherapy
- Accession number :
- edsair.doi.dedup.....eb5f06d1f6fe0d1752b81c56910e4e3d